Fidaxomicin adverse reactions
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Adverse Reactions
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of any other drug and may not reflect the rates observed in practice.
The safety of DIFICID 200 mg tablets taken twice a day for 10 days was evaluated in 564 patients with CDAD in two active-comparator controlled trials with 86.7% of patients receiving a full course of treatment.
Thirty-three patients receiving DIFICID (5.9%) withdrew from trials as a result of adverse reactions (AR). The types of AR resulting in withdrawal from the study varied considerably. Vomiting was the primary adverse reaction leading to discontinuation of dosing; this occurred at an incidence of 0.5% in both the fidaxomicin and vancomycin patients in Phase 3 studies.
| [[File:|800px|thumb]] |
The following adverse reactions were reported in <2% of patients taking DIFICID tablets in controlled trials:
Gastrointestinal Disorders
Abdominal distension, Abdominal tenderness, Dyspepsia, Dysphagia, flatulence, Intestinal obstruction, Megacolon
Investigations
Increased blood alkaline phosphatase, Decreased blood bicarbonate, Increased hepatic enzymes, Decreased platelet count
Metabolism and Nutrition Disorders
Hyperglycemia, Metabolic Acidosis
Skin and Subcutaneous Tissue Disorders
Drug eruption, Pruritus, Rash
Post Marketing Experience
Adverse reactions reported in the post marketing setting arise from a population of unknown size and are voluntary in nature. As such, reliability in estimating their frequency or in establishing a causal relationship to drug exposure is not always possible.
Hypersensitivity reactions (dyspnea, angioedema, rash, and pruritus) have been reported.[1]
References
Adapted from the FDA Package Insert.